HARLEYSVILLE, PA. February 23, 2024 – Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Vedanta Biosciences, a clinical stage life sciences company that designs and manufactures proprietary, orally delivered bacterial therapies.

Ali Rajabi-Siahboomi, Vice President and Chief Innovation Officer at Colorcon, said, “Vedanta Biosciences is aligned with Colorcon Ventures’ interest in emerging classes of drugs for oral administration. The company’s unique approach within microbial therapeutics has the potential to offer safer and more efficacious treatments for a number of indications. Vedanta has also revolutionized the manufacturing of defined bacterial consortia at scale, which adds significant value to the sector. We look forward to supporting Vedanta Biosciences as they realize the full potential of their platform technology.”

Bernat Olle, Vedanta Biosciences’ CEO, said, “We are pleased to have Colorcon Ventures support us as we move our programs through clinical development and expand our pipeline. Colorcon’s formulation expertise will augment our ability to provide patients with new and effective therapies.”

Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Action Fund, Bill & Melinda Gates Foundation, K2 HealthVentures, Pfizer, PureTech Health, Skyviews Life Science, and others.